Skip to main content

Peer Review reports

From: Rationale and design of the German-speaking myeloma multicenter group (GMMG) trial HD6: a randomized phase III trial on the effect of elotuzumab in VRD induction/consolidation and lenalidomide maintenance in patients with newly diagnosed myeloma

Original Submission
7 Feb 2018 Submitted Original manuscript
6 Apr 2018 Author responded Author comments - Hans Salwender
Resubmission - Version 2
6 Apr 2018 Submitted Manuscript version 2
19 Feb 2019 Author responded Author comments - Hans Salwender
23 Aug 2018 Reviewed Reviewer Report - Wilson I. Gonsalves
30 Jan 2019 Reviewed Reviewer Report - Sarah Holstein
Resubmission - Version 3
19 Feb 2019 Submitted Manuscript version 3
24 Feb 2019 Author responded Author comments - Hans Salwender
Resubmission - Version 4
24 Feb 2019 Submitted Manuscript version 4
6 Mar 2019 Author responded Author comments - Hans Salwender
Resubmission - Version 5
6 Mar 2019 Submitted Manuscript version 5
3 Apr 2019 Author responded Author comments - Hans Salwender
Resubmission - Version 6
3 Apr 2019 Submitted Manuscript version 6
Publishing
12 Apr 2019 Editorially accepted
28 May 2019 Article published 10.1186/s12885-019-5600-x

You can find further information about peer review here.

Back to article page